Home/Filings/4/0000950170-25-086697
4//SEC Filing

Kalif Eliyahu Sharon 4

Accession 0000950170-25-086697

CIK 0000818686other

Filed

Jun 15, 8:00 PM ET

Accepted

Jun 16, 4:03 PM ET

Size

5.4 KB

Accession

0000950170-25-086697

Insider Transaction Report

Form 4
Period: 2025-06-12
Kalif Eliyahu Sharon
EVP, Chief Financial Officer
Transactions
  • Sale

    Ordinary Shares

    2025-06-12$17.08/sh55,775$952,464403,288 total
Footnotes (3)
  • [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  • [F2]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 29, 2024.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.055 to $17.12, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Documents

1 file

Issuer

TEVA PHARMACEUTICAL INDUSTRIES LTD

CIK 0000818686

Entity typeother

Related Parties

1
  • filerCIK 0001798443

Filing Metadata

Form type
4
Filed
Jun 15, 8:00 PM ET
Accepted
Jun 16, 4:03 PM ET
Size
5.4 KB